Generic Name: enasidenib

Pronunciation: N/A

Abbreviation: N/A

Other Market Name: N/A

Drug Class: Targeted Therapy Medications

Company: Celgene-Agios

Approval Status: Approved

Generic Version Available: No

Experimental Code: N/A

Drug Indication

Idhifa is an IDH2 inhibitor approved for adults with acute myeloid leukemia with IDH2 mutations that does not respond to prior treatment.

General Info

Idhifa inhibits isocitrate dehydrogenase-2, an enzyme that plays a role in cellular metabolism. The drug targets mutant versions of the enzyme produced by cancerous blood cells. A study showed that 23 percent of people who used Idhifa achieved complete remission and normalization of blood cell counts. It was approved in 2017.


Dosing Info:

Idhifa is a tablet taken once daily until disease progression or unacceptable side effects occur.

Side Effects

Idhifa is usually well tolerated. The most common side effects include nausea, vomiting, diarrhea, loss of appetite and elevated. The Idhifa label has a warning about differentiation syndrome, a set of symptoms including swelling and shortness of breath that can occur when myeloid cells mature. Idhifa may cause fetal harm if used during pregnancy.

For More Info:

Patient Assistance Program Info:

Last Reviewed: November 29, 2018